TRIL.TO

Trillium Therapeutics Inc. [TRIL.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TRIL.TO Stock Summary

In the News

TRIL.TO Financial details

Company Rating
-
Market Cap
0
Income
65.08M
Revenue
43K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
16 Mar 2022
P/E
-24.87
Forward P/E
-
PEG
1.66
P/S
-
P/B
5.29
P/C
-
P/FCF
-
Quick Ratio
13.64
Current Ratio
13.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.82
EPS next Y
-
EPS next Q
-
EPS this Y
-57.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-20%
ROE
-43%
ROC
-0.22%
Gross Margin
-
Oper. Margin
-41524%
Profit Margin
-40099%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
23.22-23.45
52W High
-
52W Low
-
RSI
-
Rel Volume
0.47
Avg Volume
127.47K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.90458
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
VTI
TSLA
0YXG.L
1YD.DE
VFINX
Same Sector
TFX
MTEM
4592.T
HCA
ENTX
Check Those
VIGI
KEY.TO
001880.KS
910861.TW
JTEKF
Similar Market Cap
GV.PA
MRC.TO
ONWARDTEC.NS
NSKOG.OL
8299.TWO

Company Profile

Healthcare Biotechnology

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.